UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Jun

    07

    Disease Spotlight: Hidradenitis Suppurativa

    At UCB, people are at the heart of everything we do and part of our commitment to delivering impactful solutions for people whose lives have been challenged by severe disease is by deeply understanding their disease. This week is Hidradenitis Suppurativa (HS) Awareness Week and we’re sharing information on this lesser-known inflammatory, chronic autoimmune skin disease.

    Jun

    06

    UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

    Today, UCB was pleased to host Her Royal Highness Princess Astrid of Belgium (HRH), Belgian dignitaries, and Belgian business leaders to visit our U.S. headquarters in Atlanta, Georgia.

    Jun

    01

    Life with MG & What I Wish For Everyone Who is Diagnosed

    May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)